Viome Life Sciences, Inc.
PrivateLast Round
Series D
Sep 10, 2024
Est. Valuation
$339M
Total Funding Raised
$337.5M
Company Overview
Viome Life Sciences, Inc. is a biotechnology company that provides at-home health tests analyzing microbial and human gene expressions to offer personalized nutrition and supplement recommendations.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, D2C Brands, Subscription Commerce
Business Model
B2C
Customer Profile
Subscription SaaS, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Viome Life Sciences, Inc. Comparables
Compare Viome Life Sciences, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ZOE | 87% | |
| Ombre | 83% | |
| Elo Health | 79% |
Viome Life Sciences, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 10, 2024 | ||||
| Series C Extension | Aug 18, 2023 | ||||
| Series C | Oct 18, 2022 | ||||
| Convertible Debt | Nov 10, 2021 | ||||
| Debt | Feb 10, 2021 | ||||
Series B | Nov 27, 2019 |
Viome Life Sciences, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ocgrow Ventures | Convertible Debt, Series C |
| Ezaki Glico Co., Ltd. | Convertible Debt, Series B, Series C |
| Khosla Ventures | Convertible Debt, Series B, Series D, Series B Extension, Series C, Series A, Series C Extension |
| Bold Capital Group | Convertible Debt, Series B, Series C |
| WRG Ventures | Series D, Series C Extension |
| WestRiver Group | Convertible Debt, Series C |
| BOLD Capital Partners | Series A, Series B, Series D, Series C Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 18, 2025
Integration to leverage secure and scalable infrastructure services.
- Apr 14, 2025
Launched AI-powered RNA diagnostics for precision nutrition.
Recent news
Latest coverage and updates
- partners_withSep 28, 2026
Viome, Inc. partnered with GMC on Sep 25th '26.
- launchesSep 14, 2026
Viome, Inc. launches AI microbiome tracker.
- acquiresAug 12, 2026
Viome, Inc. acquired Circulate Health Inc. for $15M on Aug 25th '26.
Viome Life Sciences, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Viome Life Sciences, Inc.'s valuation, stock price, and market status.
Is Viome a public or private company?
Viome is a private company.
What is the current stock price of Viome?
Viome is a private company with no public stock price. No recent secondary market data is available.
How much is Viome worth (valuation)?
Valuation information for Viome is not publicly available.
Can I buy Viome stock?
Viome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Viome's last funding round?
Viome's most recent funding round was Series D on September 10, 2024.
Who are the main investors in Viome?
Key investors in Viome include Khosla Ventures, BOLD Capital Partners, Bold Capital.
Will Viome IPO soon?
No public IPO plans have been announced for Viome.
How can I track Viome secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Viome's secondary market activity and sign up for updates.